136236-51-6 | (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine

Packsize	Purity	Availability	Price	Discounted Price
1mg	99+%	in stock	$7.00	$5.00
50mg	99+%	in stock	$10.00	$7.00

Description

• Catalog Number: AB55731
• Chemical Name: (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine
• CAS Number: 136236-51-6
• Molecular Formula: C12H13N
• Molecular Weight: 171.2383
• MDL Number: MFCD00866571
• SMILES: C#CCN[C@@H]1CCc2c1cccc2
• NSC Number: 759639

Computed Properties

• Complexity: 212
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 13
• Hydrogen Bond Acceptor Count: 1
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2
• XLogP3: 1.8

Literature

• Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro.

  International journal of pharmaceutics 20121115

• Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.

  Journal of medicinal chemistry 20121011

• Rasagiline: a guide to its use in Parkinson's disease.

  CNS drugs 20120901

• Proteoliposome-based capillary electrophoresis for screening membrane protein inhibitors.

  Journal of chromatographic science 20120801

• Therapies in Parkinson's disease.

  Current opinion in neurology 20120801

• Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.

  Molecular neurobiology 20120801

• Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.

  The International journal of neuroscience 20120701

• Drugs for treating Parkinson disease.

  Nursing 20120701

• Development of Parkinson's disease in patients with Narcolepsy.

  Journal of neural transmission (Vienna, Austria : 1996) 20120601

• Hyposmia in Parkinson's disease.

  Psychiatry and clinical neurosciences 20120601

• Livedo reticularis associated with rasagiline (azilect).

  Journal of drugs in dermatology : JDD 20120601

• The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?

  Journal of clinical pharmacology 20120501

• Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.

  Mechanisms of ageing and development 20120501

• Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B).

  Bioorganic & medicinal chemistry 20120501

• Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.

  Journal of neural transmission (Vienna, Austria : 1996) 20120401

• Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

  Drugs 20120326

• Modeling mitochondrial dysfunctions in the brain: from mice to men.

  Journal of inherited metabolic disease 20120301

• Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.

  Retina (Philadelphia, Pa.) 20120301

• Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.

  European journal of neurology 20120201

• Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.

  The International journal of neuroscience 20120101

• A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.

  PloS one 20120101

• Tinnitus: network pathophysiology-network pharmacology.

  Frontiers in systems neuroscience 20120101

• Risk of falls in Parkinson's disease: a cross-sectional study of 160 patients.

  Parkinson's disease 20120101

• Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.

  Neuropsychiatric disease and treatment 20120101

• From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20120101

• Restless legs syndrome responsive to rasagiline treatment: a case report.

  Clinical neuropharmacology 20120101

• Combined beneficial effect of rasagiline on motor function and depression in de novo PD.

  Clinical neuropharmacology 20120101

• α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease.

  PloS one 20120101

• Schisandrin B as a hormetic agent for preventing age-related neurodegenerative diseases.

  Oxidative medicine and cellular longevity 20120101

• Adjunctive therapy in Parkinson's disease: the role of rasagiline.

  Neuropsychiatric disease and treatment 20120101

• Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.

  Bioorganic & medicinal chemistry 20111215

• Drugs in traffic: the road to approval.

  Nature medicine 20111206

• Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

  European journal of neurology 20111201

• Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

  CNS drugs 20111201

• Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.

  Movement disorders : official journal of the Movement Disorder Society 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.

  European journal of pharmacology 20111130

• In the news: Doubt over Azilect® relabeling.

  Nature reviews. Neurology 20111115

• Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.

  Movement disorders : official journal of the Movement Disorder Society 20111101

• Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.

  Current topics in medicinal chemistry 20111101

• Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

  The neurologist 20111101

• An effective novel delivery strategy of rasagiline for Parkinson's disease.

  International journal of pharmaceutics 20111031

• The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20111001

• Advanced strategies for treatment of Parkinson's disease: the role of early treatment.

  The American journal of managed care 20111001

• Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.

  The International journal of neuroscience 20110901

• The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.

  Movement disorders : official journal of the Movement Disorder Society 20110815

• Disease modification in Parkinson's disease.

  Drugs & aging 20110801

• Safety of rasagiline for the treatment of Parkinson's disease.

  Expert opinion on drug safety 20110701

• TVP1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume overload-induced congestive heart failure.

  Circulation. Heart failure 20110701

• Treatment in late Parkinson's disease.

  Annals of Indian Academy of Neurology 20110701

• Motor fluctuations and dyskinesias (diagnosis and management).

  Annals of Indian Academy of Neurology 20110701

• Initiation of treatment in early PD (evidences based).

  Annals of Indian Academy of Neurology 20110701

• The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion.

  British journal of pharmacology 20110601

• Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.

  Expert opinion on pharmacotherapy 20110601

• Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date.

  Current genomics 20110601

• Medical management of Parkinson's disease: focus on neuroprotection.

  Current neuropharmacology 20110601

• A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

  The Lancet. Neurology 20110501

• Milestones in Parkinson's disease therapeutics.

  Movement disorders : official journal of the Movement Disorder Society 20110501

• MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae.

  Journal of proteome research 20110401

• Using entropy of drug and protein graphs to predict FDA drug-target network: theoretic-experimental study of MAO inhibitors and hemoglobin peptides from Fasciola hepatica.

  European journal of medicinal chemistry 20110401

• Determination of minimal clinically important change in early and advanced Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20110401

• Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?

  Antioxidants & redox signaling 20110301

• Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

  Journal of neural transmission (Vienna, Austria : 1996) 20110301

• Hemiparkinsonism-hemiatrophy syndrome.

  Archives of Iranian medicine 20110301

• Rasagiline-induced serotonin syndrome.

  Movement disorders : official journal of the Movement Disorder Society 20110301

• MAO-inhibitors in Parkinson's Disease.

  Experimental neurobiology 20110301

• Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.

  Drugs & aging 20110201

• MAO inhibitors.

  Cleveland Clinic journal of medicine 20110201

• Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.

  Journal of glaucoma 20110101

• Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.

  Neurochemistry international 20110101

• Selegiline and rasagiline: twins or distant cousins?

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110101

• Iron and mechanisms of neurotoxicity.

  International journal of Alzheimer's disease 20110101

• From L-dopa to dihydroxyphenylacetaldehyde: a toxic biochemical pathway plays a vital physiological function in insects.

  PloS one 20110101

• Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.

  BMC pharmacology 20110101

• The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

  International journal of molecular sciences 20110101

• Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

  Patient preference and adherence 20110101

• Available and emerging treatments for Parkinson's disease: a review.

  Drug design, development and therapy 20110101

• Placebo - More hatred than love.

  Journal of neurosciences in rural practice 20110101

• Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons.

  PloS one 20110101

• The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

  Journal of neuroinflammation 20110101

• Influence of stochastic gene expression on the cell survival rheostat after traumatic brain injury.

  PloS one 20110101

• Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.

  Current medicinal chemistry 20110101

• Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

  BMC neurology 20110101

• [The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101

• The pharmacology of selegiline.

  International review of neurobiology 20110101

• Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.

  International review of neurobiology 20110101

• Rasagiline in Parkinson's disease.

  International review of neurobiology 20110101

• Selective inhibitors of monoamine oxidase type B and the 'cheese effect'.

  International review of neurobiology 20110101

• Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

  Advances in pharmacological sciences 20110101

• The evidence for disease modification in Parkinson's disease.

  The International journal of neuroscience 20110101

• The promise of neuroprotective agents in Parkinson's disease.

  Frontiers in neurology 20110101

• Strategies for reducing or preventing the generation of oxidative stress.

  Oxidative medicine and cellular longevity 20110101

• Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives.

  Oxidative medicine and cellular longevity 20110101

• Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

  Journal of drug delivery 20110101

• Variable initial swing side and prolonged double limb support represent abnormalities of the first three steps of gait initiation in patients with Parkinson's disease with freezing of gait.

  Frontiers in neurology 20110101

• Lack of information and access to advanced treatment for Parkinson's disease patients.

  Journal of multidisciplinary healthcare 20110101

• Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

  ISRN neurology 20110101

• Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.

  Journal of clinical pharmacology 20101201

• Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

  Neurochemical research 20101201

• Seniors with Parkinson's disease: initial medical treatment.

  Journal of clinical neurology (Seoul, Korea) 20101201

• The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

  Neurology 20101123

• The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

  Neurology 20101123

• Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

  Progress in neurobiology 20101101

• Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.

  Neurochemistry international 20101101

• Does rasagiline have a disease-modifying effect on Parkinson's disease?

  Current neurology and neuroscience reports 20101101

• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

  Archives of toxicology 20101101

• [Rasagiline: effectiveness and protection in Parkinson's disease].

  Revista de neurologia 20101101

• [Disease-modifying therapies in PD].

  Rinsho shinkeigaku = Clinical neurology 20101101

• Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease.

  European journal of neurology 20100901

• Isolated delusional syndrome in Parkinson's Disease.

  Parkinsonism & related disorders 20100901

• Slowing the decline.

  Nature 20100826

• Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.

  The American journal of geriatric pharmacotherapy 20100801

• Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.

  Parkinsonism & related disorders 20100701

• Rasagiline improves learning and memory in young healthy rats.

  Behavioural pharmacology 20100701

• Transdermal rotigotine for the perioperative management of Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20100701

• Discordant effects of rasagiline doses in Parkinson disease.

  Nature reviews. Neurology 20100701

• Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.

  Current Alzheimer research 20100601

• The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.

  The Journal of pharmacology and experimental therapeutics 20100601

• Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.

  The Lancet. Neurology 20100601

• Long-term efficacy of rasagiline in early Parkinson's disease.

  The International journal of neuroscience 20100601

• Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.

  Experimental neurobiology 20100601

• A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.

  Biological psychiatry 20100501

• Parkinson's disease and motor fluctuations.

  Current treatment options in neurology 20100501

• Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

  Neurology 20100406

• The delayed-start study in Parkinson disease: can't satisfy everyone.

  Neurology 20100406

• Reply to Drs. Olanow and Rascol.

  Neurology 20100406

• The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.

  Journal of neurochemistry 20100301

• [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].

  Fortschritte der Neurologie-Psychiatrie 20100301

• Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.

  Nature reviews. Neurology 20100301

• Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.

  The American journal of managed care 20100301

• Rasagiline in Parkinson's disease.

  The New England journal of medicine 20100218

• Rasagiline in Parkinson's disease.

  The New England journal of medicine 20100218

• TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.

  The Journal of pharmacology and experimental therapeutics 20100201

• Levodopa delivery systems: advancements in delivery of the gold standard.

  Expert opinion on drug delivery 20100201

• Skin cancer and Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20100130

• Selective MAO-B inhibitors have low potential for the tyramine effect.

  Movement disorders : official journal of the Movement Disorder Society 20100115

• The effect of antiparkinsonian drugs on oxidative stress induced pathological [3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices.

  Neuropharmacology 20100101

• Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

  BMC neuroscience 20100101

• Anticipatory modulation of digit placement for grasp control is affected by Parkinson's disease.

  PloS one 20100101

• Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.

  Neuro-degenerative diseases 20100101

• The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment.

  Neuro-degenerative diseases 20100101

• The role of rasagiline in the treatment of Parkinson's disease.

  Clinical interventions in aging 20100101

• GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons.

  BMC neuroscience 20100101

• Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.

  Journal of Alzheimer's disease : JAD 20100101

• Methods for studying redox cycling of thioredoxin in mediating preconditioning-induced survival genes and proteins.

  Methods in enzymology 20100101

• What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?

  Neuroepidemiology 20100101

• Delayed start, rapid solution?

  Neuroepidemiology 20100101

• Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.

  Core evidence 20100101

• Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.

  Current pharmaceutical design 20100101

• Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.

  Neuropsychobiology 20100101

• Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

  Clinical drug investigation 20100101

• Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

  Neuropsychiatric disease and treatment 20100101

• Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease.

  BMC neurology 20100101

• [Rasagiline is not for all Parkinson disease patients: the ADAGIO study].

  Nederlands tijdschrift voor geneeskunde 20100101

• The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.

  Frontiers in neuroscience 20100101

• [Statistical significance or clinical relevance?].

  Nederlands tijdschrift voor geneeskunde 20100101

• Treatment of advanced Parkinson's disease.

  Parkinson's disease 20100101

• [Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

• Biopsable neural tissues: toward new biomarkers for Parkinson's disease?

  Frontiers in psychiatry 20100101

• Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability.

  ClinicoEconomics and outcomes research : CEOR 20100101

• Mao-B inhibitor know-how: back to the pharm.

  Neurology 20091208

• Parkinson's disease I: glucocerebrosidase mutations, family history of melanoma and questionable effects of rasagiline.

  Journal of neurology 20091201

• New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy.

  Parkinsonism & related disorders 20091201

• Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram.

  Progress in neuro-psychopharmacology & biological psychiatry 20091113

• Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

  Journal of neural transmission (Vienna, Austria : 1996) 20091101

• Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20091101

• Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival.

  Journal of neural transmission (Vienna, Austria : 1996) 20091101

• Rasagiline-induced spontaneous ejaculation.

  Movement disorders : official journal of the Movement Disorder Society 20091030

• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  The New England journal of medicine 20090924

• Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan.

  Neurotoxicity research 20090801

• Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

  Expert review of neurotherapeutics 20090801

• Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres.

  Journal of pharmaceutical and biomedical analysis 20090712

• Alzheimer's disease: new approaches to drug discovery.

  Current opinion in chemical biology 20090601

• Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

  International journal of molecular sciences 20090601

• Validation of the freezing of gait questionnaire in patients with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20090415

• MAO-B inhibitor know-how: back to the pharm.

  Neurology 20090414

• Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.

  Neurotoxicity research 20090401

• Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20090315

• Involvement of the subthalamic nucleus in engagement with behaviourally relevant stimuli.

  The European journal of neuroscience 20090301

• 'Bad guys' among the antiparkinsonian drugs.

  Psychiatria Danubina 20090301

• Targeting the progression of Parkinson's disease.

  Current neuropharmacology 20090301

• Neuroprotection by rasagiline in thiamine deficient rats.

  Brain research 20090223

• Mechanisms compensating for dopamine loss in early Parkinson disease.

  Neurology 20090217

• [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].

  Ideggyogyaszati szemle 20090130

• Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101

• Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

  BMC medical genomics 20090101

• Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?

  The open neurology journal 20090101

• Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.

  European review for medical and pharmacological sciences 20090101

• A review of ropinirole prolonged release in Parkinson's disease.

  Clinical interventions in aging 20090101

• Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture.

  PloS one 20090101

• Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons.

  PloS one 20090101

• [Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.

  Drugs & aging 20090101

• Role of rasagiline in treating Parkinson's disease: Effect on disease progression.

  Therapeutics and clinical risk management 20090101

• Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.

  Cases journal 20090101

• Sleep attack associated to rotigotine.

  Clinical neuropharmacology 20090101

• An unusual case of spontaneous multi vessel coronary artery dissection in an elderly patient: a case report.

  Cases journal 20090101

• Screening the methanol extracts of some Iranian plants for acetylcholinesterase inhibitory activity.

  Research in pharmaceutical sciences 20090101

• Drug selection and timing of initiation of treatment in early Parkinson's disease.

  Annals of neurology 20081201

• A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

  Movement disorders : official journal of the Movement Disorder Society 20081115

• Rapid and sensitive liquid chromatography-tandem mass spectrometry: assay development, validation and application to a human pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115

• The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

  Expert opinion on pharmacotherapy 20081101

• Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)).

  Acta crystallographica. Section C, Crystal structure communications 20081101

• Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081001

• [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

  Fortschritte der Neurologie-Psychiatrie 20081001

• Neuropharmacology.

  Indian journal of pharmacology 20081001

• The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.

  Chemico-biological interactions 20080925

• Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.

  Hypertension (Dallas, Tex. : 1979) 20080901

• TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.

  Journal of cardiovascular pharmacology 20080901

• Rasagiline in neurodegeneration.

  Experimental neurology 20080801

• Clorgyline and other propargylamine derivatives as inhibitors of succinate-dependent H(2)O(2) release at NADH:UBIQUINONE oxidoreductase (Complex I) in brain mitochondria.

  Journal of bioenergetics and biomembranes 20080801

• The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.

  Neuropsychiatric disease and treatment 20080801

• Current approaches to the treatment of Parkinson's disease.

  Neuropsychiatric disease and treatment 20080801

• New frontiers in the pharmacological management of Parkinson's disease.

  Drugs of today (Barcelona, Spain : 1998) 20080701

• Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.

  Journal of neurochemistry 20080601

• [Rasagiline in Parkinson's disease].

  Neurologia (Barcelona, Spain) 20080501

• Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.

  Experimental neurology 20080401

• Progress in neuroprotection in Parkinson's disease.

  European journal of neurology 20080401

• Protection against Parkinson's disease progression: clinical experience.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20080401

• Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

  Genes, brain, and behavior 20080301

• Discovery and characterization of a putrescine oxidase from Rhodococcus erythropolis NCIMB 11540.

  Applied microbiology and biotechnology 20080301

• [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20080301

• New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins.

  Bioorganic & medicinal chemistry 20080215

• Rasagiline improves freezing in a patient with primary progressive freezing gait.

  Movement disorders : official journal of the Movement Disorder Society 20080215

• Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors.

  Journal of biomolecular structure & dynamics 20080201

• COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.

  Neuropsychiatric disease and treatment 20080201

• Drugs for Parkinson’s disease: levodopa is still the gold standard.

  Neuropsychiatric disease and treatment 20080201

• Rasagiline in treatment of Parkinson's disease.

  Neuropsychiatric disease and treatment 20080201

• Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

  Journal of neural transmission (Vienna, Austria : 1996) 20080101

• Spotlight on rasagiline in Parkinson's disease.

  CNS drugs 20080101

• Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.

  CNS drugs 20080101

• The clinical pharmacology of intranasal l-methamphetamine.

  BMC clinical pharmacology 20080101

• Medical treatment of freezing of gait.

  Movement disorders : official journal of the Movement Disorder Society 20080101

• Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.

  BMC neuroscience 20080101

• [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20080101

• Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20071201

• Pharmacotherapy for Parkinson's disease.

  Pharmacotherapy 20071201

• Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

  Pharmacotherapy 20071201

• Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.

  Annals of the New York Academy of Sciences 20071201

• Parkinson disease: an incremental challenge.

  South Dakota medicine : the journal of the South Dakota State Medical Association 20071201

• Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.

  Journal of neurochemistry 20071001

• Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway.

  Neurochemical research 20071001

• Transdermal selegiline for the treatment of major depressive disorder.

  Neuropsychiatric disease and treatment 20071001

• Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

  Clinical therapeutics 20070901

• Plasma amino acids and neopterin in healthy persons with Down's syndrome.

  Journal of neural transmission (Vienna, Austria : 1996) 20070801

• Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

  Current opinion in neurology 20070801

• The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.

  Molecular pharmacology 20070601

• Rasagiline as a therapy for Parkinson's disease (PD).

  The American journal of geriatric pharmacotherapy 20070601

• Editorial.

  Therapeutics and clinical risk management 20070601

• Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.

  Therapeutics and clinical risk management 20070601

• Biological targets for isatin and its analogues: Implications for therapy.

  Biologics : targets & therapy 20070601

• Advances in the pharmacologic management of early Parkinson disease.

  The neurologist 20070501

• Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20070430

• The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection.

  Antioxidants & redox signaling 20070201

• Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.

  Neurobiology of disease 20070101

• Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

  Journal of neural transmission (Vienna, Austria : 1996) 20070101

• Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

  Clinical neuropharmacology 20070101

• From a Parkinson's disease expert: Rasagiline and the future of therapy.

  Molecular neurodegeneration 20070101

• Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

  CNS drugs 20070101

• Rasagiline: a review of its use in the management of Parkinson's disease.

  Drugs 20070101

• Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

  Drugs & aging 20070101

• Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology.

  BMC neuroscience 20070101

• Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.

  Journal of neural transmission. Supplementum 20070101

• New strategies in motor parkinsonism.

  Parkinsonism & related disorders 20070101

• Rasagiline (Azilect) for Parkinson's disease.

  The Medical letter on drugs and therapeutics 20061204

• L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.

  Pharmacology, biochemistry, and behavior 20061201

• Rasagiline. Parkinson's disease: a simple me-too.

  Prescrire international 20061201

• The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

  Current Alzheimer research 20061201

• Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.

  Neurotoxicity research 20061201

• Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

  The American journal of geriatric pharmacotherapy 20061201

• Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.

  British journal of pharmacology 20061101

• Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.

  Journal of the neurological sciences 20061025

• New pharmacologic horizons in the treatment of Parkinson disease.

  Neurology 20061010

• Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

  Movement disorders : official journal of the Movement Disorder Society 20061001

• A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061001

• Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.

  Neurology 20060523

• Clinical trials with rasagiline: evidence for short-term and long-term effects.

  Neurology 20060523

• Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060515

• [Diagnosis and therapy of idiopathic Parkinson's disease].

  MMW Fortschritte der Medizin 20060515

• Safety of rasagiline in elderly patients with Parkinson disease.

  Neurology 20060509

• Rasagiline improves quality of life in patients with early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20060501

• Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

  Neurology 20060411

• Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.

  The Annals of pharmacotherapy 20060401

• Rasagiline -- is there a place for this drug in managing Parkinson's disease?

  International journal of clinical practice 20060201

• Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.

  International journal of clinical practice 20060201

• N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.

  Journal of neural transmission (Vienna, Austria : 1996) 20060101

• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

  British journal of pharmacology 20060101

• Drugs in development for Parkinson's disease: an update.

  Current opinion in investigational drugs (London, England : 2000) 20060101

• CROPPER: a metagene creator resource for cross-platform and cross-species compendium studies.

  BMC bioinformatics 20060101

• Concerning neuroprotective therapy for Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.

  Journal of neural transmission. Supplementum 20060101

• New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate.

  Journal of the American Pharmacists Association : JAPhA 20060101

• New drug treatment for Parkinson's disease.

  FDA consumer 20060101

• Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.

  Journal of neural transmission. Supplementum 20060101

• Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.

  Journal of neural transmission. Supplementum 20060101

• The use of rasagiline in Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.

  Journal of medicinal chemistry 20051229

• Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons.

  Biochemical pharmacology 20051125

• Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20051101

• Present and future drug treatment for Parkinson's disease.

  Journal of neurology, neurosurgery, and psychiatry 20051101

• Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

  Expert review of neurotherapeutics 20051101

• Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.

  Bioorganic & medicinal chemistry letters 20051015

• The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.

  British journal of pharmacology 20051001

• Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.

  Journal of neurochemistry 20051001

• Rasagiline in the pharmacotherapy of Parkinson's disease--a review.

  Expert opinion on pharmacotherapy 20051001

• In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051001

• Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

  Journal of clinical neurology (Seoul, Korea) 20051001

• [Rasagiline in motor fluctuations].

  Fortschritte der Neurologie-Psychiatrie 20050901

• Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model.

  Journal of neural transmission (Vienna, Austria : 1996) 20050801

• Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.

  Journal of clinical pharmacology 20050801

• Reexamination of the TEMPO Study.

  Archives of neurology 20050801

• Rasagiline.

  Nature reviews. Drug discovery 20050801

• Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.

  Annals of the New York Academy of Sciences 20050801

• [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].

  Medizinische Monatsschrift fur Pharmazeuten 20050701

• Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.

  Drugs of today (Barcelona, Spain : 1998) 20050601

• Parkinson's disease. Diagnosis and the initiation of therapy.

  Minerva medica 20050601

• Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

  Movement disorders : official journal of the Movement Disorder Society 20050501

• Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.

  Brain research. Brain research reviews 20050401

• Novel pharmacological strategies for motor complications in Parkinson's disease.

  Expert opinion on investigational drugs 20050401

• Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells.

  Neuropharmacology 20050301

• Rasagiline for motor complications in Parkinson's disease.

  Lancet (London, England) 20050301

• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  Lancet (London, England) 20050301

• Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

  Mechanisms of ageing and development 20050201

• A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

  Archives of neurology 20050201

• Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.

  Journal of neuroscience research 20050101

• Movement disorders: understanding clinical trials.

  The Lancet. Neurology 20050101

• Rasagiline.

  Drugs & aging 20050101

• Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.

  Movement disorders : official journal of the Movement Disorder Society 20050101

• Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

  CNS drug reviews 20050101

• Alternatives to levodopa in the initial treatment of early Parkinson's disease.

  Drugs & aging 20050101

• [The early therapy challenge].

  Krankenpflege Journal 20050101

• [Are there innovations in the treatment of Parkinson's disease?].

  Praxis 20041103

• Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.

  Neurology 20041012

• Clinical trials of neuroprotection for Parkinson's disease.

  Neurology 20041012

• Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

  British journal of pharmacology 20041001

• Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.

  Journal of neural transmission (Vienna, Austria : 1996) 20041001

• Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.

  Pharmacotherapy 20041001

• Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040901

• Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.

  Journal of neurology 20040901

• Drug treatment of Parkinson's disease.

  Dialogues in clinical neuroscience 20040901

• Clinical applications of MAO-inhibitors.

  Current medicinal chemistry 20040801

• Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.

  Movement disorders : official journal of the Movement Disorder Society 20040801

• Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.

  Neuropharmacology 20040701

• Neuroprotection in Parkinson's disease: an elusive goal.

  Current neurology and neuroscience reports 20040701

• Drugs in development for Parkinson's disease.

  Current opinion in investigational drugs (London, England : 2000) 20040701

• Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

  Experimental neurology 20040601

• Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.

  Journal of neurochemistry 20040601

• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.

  Neurochemistry international 20040501

• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  Archives of neurology 20040401

• Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.

  Journal of medicinal chemistry 20040325

• Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.

  Journal of medicinal chemistry 20040325

• Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.

  Neuroscience letters 20040130

• Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?

  BioEssays : news and reviews in molecular, cellular and developmental biology 20040101

• Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.

  Neurotoxicology 20040101

• Recent approaches to novel anti-Alzheimer therapy.

  Current pharmaceutical design 20040101

• The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031201

• Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity.

  British journal of cancer 20031117

• Rasagiline: an anti-Parkinson drug with neuroprotective activity.

  Expert review of neurotherapeutics 20031101

• The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.

  Biochemical pharmacology 20031015

• L-DOPA increases noradrenaline turnover in central and peripheral nervous systems.

  Neuropharmacology 20030901

• Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens.

  European journal of pharmacology 20030711

• Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.

  Neuroscience letters 20030508

• Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.

  Annals of the New York Academy of Sciences 20030501

• Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.

  Journal of enzyme inhibition and medicinal chemistry 20030401

• Monoamine oxidase inhibitors--is it time to up the TEMPO?

  The Lancet. Neurology 20030301

• Protein 4.1N is required for translocation of inositol 1,4,5-trisphosphate receptor type 1 to the basolateral membrane domain in polarized Madin-Darby canine kidney cells.

  The Journal of biological chemistry 20030207

• Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.

  Inflammopharmacology 20030101

• A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

  Archives of neurology 20021201

• Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.

  Neuropharmacology 20021201

• Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.

  Journal of medicinal chemistry 20021121

• Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021001

• Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan.

  Journal of neurochemistry 20020801

• Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.

  Movement disorders : official journal of the Movement Disorder Society 20020701

• An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.

  Neuroscience letters 20020628

• Rasagiline. Teva Pharmaceutical.

  Current opinion in investigational drugs (London, England : 2000) 20020501

• Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines.

  Journal of neural transmission (Vienna, Austria : 1996) 20020501

• Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.

  Mechanisms of ageing and development 20020430

• The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.

  Journal of neural transmission (Vienna, Austria : 1996) 20020401

• Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.

  Parkinsonism & related disorders 20020301

• Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells.

  European journal of pharmacology 20020111

• Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.

  Neurotoxicology and teratology 20020101

• Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

  Cellular and molecular neurobiology 20011201

• Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.

  Journal of neurochemistry 20010801

• Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.

  Annals of the New York Academy of Sciences 20010601

• Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.

  Annals of the New York Academy of Sciences 20010601

• The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.

  Annals of the New York Academy of Sciences 20010601

• Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy.

  Annals of the New York Academy of Sciences 20010401

• Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

  British journal of pharmacology 20010101

• Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.

  Journal of neural transmission. Supplementum 19980101